Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide (2015)
- Authors:
- USP affiliated authors: HEGG, ROBERTO - FM ; MARANHAO, RAUL CAVALCANTE - FCF
- Unidades: FM; FCF
- DOI: 10.1158/1538-7445.SABCS14-P6-02-06
- Subjects: QUIMIOTERAPIA; NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA); ANTINEOPLÁSICOS; NANOCOMPOSITOS; CO-TERAPIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 75, abst. P6-02-06, May, 2015
- Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MATTAR, Andre et al. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06. Acesso em: 19 abr. 2024. , 2015 -
APA
Mattar, A., Ferreira, L. B., Gebrim, L. H., Hegg, R., & Maranhão, R. C. (2015). Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P6-02-06 -
NLM
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 19 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06 -
Vancouver
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 19 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06 - Transfer of lipids to HDL in patients with breast cancer
- One hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults
- One hour infusion of clodronate disodium for treating oncological pain due to bone metastases of solid tumors among adults
- Avaliação de captação de uma emulsão lipídica semelhante a LDL em carcinoma de mama
- Use of cholesterol-rich microemulsion that binds to low-density lipotein (LDL) receptors as avehicle for etoposide
- Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study
- A lipidic microemulsion that binds to LDL receptors abolishes the side effects of high doses of a chemotherapeutic agent
- Uptake of a cholesterol-rich emulsion by breast cancer
- Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy
- Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemothrapy
Informações sobre o DOI: 10.1158/1538-7445.SABCS14-P6-02-06 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
